SynthesisInternational journal of molecular sciences2017
Differentiated Thyroid Cancer-Treatment: State of the Art.
Synthesis in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 202 citations in OpenAlex.
- Prediction of cervical lymph node metastasis in differentiated thyroid cancer based on radiomics models.The British journal of radiology · 2024Pooled it
- FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.Thyroid : official journal of the American Thyroid Association · 2021Trial
- Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.Frontiers in endocrinology · 2021Trial
- SMART Planning of Early-Stage Health Economic Decision Models for Mechanism-Based Precision Treatments in Rare Cancers: An Application and Tool Update.PharmacoEconomics · 2026Review
- Expanding the Limits of Robotic Thyroidectomy: Management of a Rare Presentation of Thyroid Carcinoma With Supraglottic Extension.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Development of metformin-encapsulated poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles.Molecular biology reports · 2026Article
- The impact of coping styles on anxiety and depression trajectories in thyroid cancer surgery patients: a longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Dynamic Thyroglobulin Ratio as a Biomarker to Identify Papillary Thyroid Cancer Patients Who Would Benefit from a Low-Iodine Diet.Diagnostics (Basel, Switzerland) · 2026Article
- Natural product-based interventions for thyroid disorders: mechanisms and applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Integrating Robotic Bilateral Axillo-Breast Approach Thyroidectomy with Molecular Diagnostics and Artificial Intelligence in Thyroid Cancer Care.Biomolecules & therapeutics · 2026Review
- Targeting the AHR-IDO1-kynurenine pathway in TREM2Frontiers in immunology · 2026Article
- Differentiated Thyroid Cancer Recurrence and Mortality Prognostic Factors: A Retrospective Cohort Study on 350 Adult Patients.Iranian journal of otorhinolaryngology · 2026Article
- Development and reliability and validity test of the body image and social function scale for patients after thyroid cancer surgery.Asia-Pacific journal of oncology nursing · 2025Article
- Quality of life and surgical outcomes of endoscopic thyroidectomy versus open thyroidectomy in papillary thyroid carcinoma.Medicine · 2025Observational
- Review
- [Future oncology (London, England) · 2025Article
- Prediction of thyroid malignancy risk using clinical and ultrasonography features and a machine learning approach.European radiology · 2025Article
- Risk factors for lateral neck lymph node metastasis in papillary thyroid ultra micro carcinoma with implications for active surveillance.Scientific reports · 2025Article
- Bridging the deficit: Assessing knowledge gaps in thyroid cancer management amongst physicians in the Democratic Republic of Congo.World journal of clinical oncology · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has increased over the last few decades. It derives from follicular thyroid cells. Generally speaking, the prognosis is excellent. If treatment according to the current guidelines is given, cases of recurrence or persistence are rare. DTC requires special expertise by the treating physician. In recent years, new therapeutic options for these patients have become available. For this article we performed a systematic literature review with special focus on the guidelines of the American Thyroid Association, the European Association of Nuclear Medicine, and the German Society of Nuclear Medicine. For DTC, surgery and radioiodine therapy followed by levothyroxine substitution remain the established therapeutic procedures. Even metastasized tumors can be cured this way. However, in rare cases of radioiodine-refractory tumors, additional options are to be discussed. These include strict suppression of thyroid-stimulating hormone (also known as thyrotropin, TSH) and external local radiotherapy. Systemic cytostatic chemotherapy does not play a significant role. Recently, multikinase or tyrosine kinase inhibitors have been approved for the treatment of radioiodine-refractory DTC. Although a benefit for overall survival has not been shown yet, these new drugs can slow down tumor progression. However, they are frequently associated with severe side effects and should be reserved for patients with threatening symptoms only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.